At a glance
ClinicalIndex Comparison RecordN/AActive· 434 enrolled
Drug / intervention
Navitor Transcatheter Aortic valve and FlexNav Delivery systemdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
VANTAGE Clinical Trial Evaluation of TAVR Using the NAVITOR Valve in a Global Investigation
In Brief
A clinical study evaluating Navitor Transcatheter Aortic valve and FlexNav Delivery system for Symptomatic Severe Aortic Stenosis. Active but no longer recruiting, targeting 434 participants across 37 sites in 11 countries.
Detailed Summary
Evaluation of TAVR using the NAVITOR valve in a Global Investigation.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSymptomatic Severe Aortic Stenosis
CountriesAustralia, Austria, Denmark, France, Germany, Israel, Italy, Netherlands, Spain, Switzerland, United Kingdom
Collaborators--
Timeline
N/AActive
2021202220232024202520262027202820292030203120322033203420352036
First PostedMar 2021
Enrollment StartJul 2021
Primary CompletionJan 2025
TodayJul 2026
Study CompletionFeb 2036
First PostedMar 9, 2021
Enrollment StartJul 13, 2021
Primary CompletionJan 2, 2025
Study CompletionFeb 28, 2036
TodayJul 2, 2026
Enrollment to primary: 3.5 yearsPosted 5.3 years ago
Interventions
Navitor Transcatheter Aortic valve and FlexNav Delivery systemdevice
Navitor valve is indicated for transcatheter delivery in patients with symptomatic severe native aortic stenosis who are intermediate or low surgical risk. Subjects will undergo transcatheter aortic valve replacement (TAVR) with the Navitor valve and FlexNav Delivery system.